185 related articles for article (PubMed ID: 18452606)
1. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.
Kopetzki E; Jekle A; Ji C; Rao E; Zhang J; Fischer S; Cammack N; Sankuratri S; Heilek G
Virol J; 2008 May; 5():56. PubMed ID: 18452606
[TBL] [Abstract][Full Text] [Related]
2. [Viral entry as therapeutic target. Current situation of entry inhibitors].
Arenzana-Seisdedos F
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
[TBL] [Abstract][Full Text] [Related]
3. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
4. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
[TBL] [Abstract][Full Text] [Related]
5. CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability.
Ji C; Kopetzki E; Jekle A; Stubenrauch KG; Liu X; Zhang J; Rao E; Schlothauer T; Fischer S; Cammack N; Heilek G; Ries S; Sankuratri S
J Biol Chem; 2009 Feb; 284(8):5175-85. PubMed ID: 19097993
[TBL] [Abstract][Full Text] [Related]
6. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
7. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Panos G; Watson DC
Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
[TBL] [Abstract][Full Text] [Related]
8. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
9. Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection.
Lee DY; Lin X; Paskaleva EE; Liu Y; Puttamadappa SS; Thornber C; Drake JR; Habulin M; Shekhtman A; Canki M
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1231-41. PubMed ID: 20001317
[TBL] [Abstract][Full Text] [Related]
10. Highly potent chimeric inhibitors targeting two steps of HIV cell entry.
Zhao B; Mankowski MK; Snyder BA; Ptak RG; Liwang PJ
J Biol Chem; 2011 Aug; 286(32):28370-81. PubMed ID: 21659523
[TBL] [Abstract][Full Text] [Related]
11. P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions.
Giroud C; Marin M; Hammonds J; Spearman P; Melikyan GB
J Virol; 2015 Sep; 89(18):9368-82. PubMed ID: 26136569
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Entry and Membrane Fusion Inhibitors.
Xiao T; Cai Y; Chen B
Viruses; 2021 Apr; 13(5):. PubMed ID: 33922579
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
[TBL] [Abstract][Full Text] [Related]
15. An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors.
Herschhorn A; Finzi A; Jones DM; Courter JR; Sugawara A; Smith AB; Sodroski JG
PLoS One; 2011; 6(11):e26731. PubMed ID: 22069466
[TBL] [Abstract][Full Text] [Related]
16. A synthetic CD4-heparan sulfate glycoconjugate inhibits CCR5 and CXCR4 HIV-1 attachment and entry.
Baleux F; Loureiro-Morais L; Hersant Y; Clayette P; Arenzana-Seisdedos F; Bonnaffé D; Lortat-Jacob H
Nat Chem Biol; 2009 Oct; 5(10):743-8. PubMed ID: 19734912
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.
Moncunill G; Armand-Ugón M; Pauls E; Clotet B; Esté JA
AIDS; 2008 Jan; 22(1):23-31. PubMed ID: 18090388
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetics, interactions and mechanism of action of maraviroc].
Soriano V; Poveda E
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():12-6. PubMed ID: 19133216
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies.
Mostashari Rad T; Saghaie L; Fassihi A
Chem Biodivers; 2018 Oct; 15(10):e1800159. PubMed ID: 30027572
[TBL] [Abstract][Full Text] [Related]
20. P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection.
Swartz TH; Esposito AM; Durham ND; Hartmann BM; Chen BK
J Virol; 2014 Oct; 88(19):11504-15. PubMed ID: 25031337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
